US Patent 10329302 Bicyclic-fused heteroaryl or aryl compounds
Patent 10329302 was granted and assigned to Pfizer Limited on June, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+161 characters)
Article
Patent abstract
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
103293020
Date of Patent
June 25, 2019
0Patent Application Number
158626910
Date Filed
January 5, 2018
0Official Website
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
103293020
Date of Patent
June 25, 2019
0Patent Application Number
158626910
Date Filed
January 5, 2018
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 27 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10329302 Bicyclic-fused heteroaryl or aryl compounds
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10329302
Date of patent
June 25, 2019
Patent application number
15862691
Date Filed
January 5, 2018
Patent primary examiner
Find more entities like US Patent 10329302 Bicyclic-fused heteroaryl or aryl compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
